Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147939 · ClinicalTrials.gov registry record · Phase 3
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
A Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 381
- Enrollment target
- 20
- Study locations
NCT01147939: Completed Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by Clavis Pharma.
NCT01147939 is a Phase 3 study of Acute Myeloid Leukemia (AML) that has completed, run by Clavis Pharma. The registered enrollment target is 381 participants, above the 132-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (189% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01147939, a Phase 3 study of Acute Myeloid Leukemia (AML), has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 381 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).
Primary Outcome
Time from date of randomisation until the date of death
Conditions Studied
Interventions
- DRUG Investigator's Choice
- DRUG Elacytarabine
Study Locations (20)
California
- Scripps Cancer Center Clinical Research - La Jolla
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- UCLA School of Medicine, Division of Hematology/Oncology - Los Angeles
New York
- New York Presbyterian Hospital, Weill-Cornell Medical College - New York
- Memorial Sloan-Kettering - New York
- New York Medical College - Valhalla
Georgia
- Winship Cancer Institute at Emory - Atlanta
- The Blood and Marrow Transplant Group of GA - Atlanta
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University, Health Sciences Section on Hematology and Oncology - Winston-Salem
Colorado
- Rocky Mountain Blood and Bone Marrow Transplant Program - Denver
Florida
- Shands at the University of Florida - Gainesville
Indiana
- St. Francis Hospital and Health Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT01147939 record still lists
NCT01147939 is an interventional study that assigns participants to a tested intervention. The registered 381 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (189% higher).
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Investigator's Choice is the first listed.
NCT01147939 names 20 study sites across 13 states, led by California, New York, Georgia.
Frequently Asked Questions
What is clinical trial NCT01147939 about?
NCT01147939 is a clinical study titled "Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)". The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).
What is the current status of trial NCT01147939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2010-06. Estimated completion is 2013-06.
What conditions does trial NCT01147939 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT01147939?
The interventions under investigation include: Investigator's Choice (DRUG), Elacytarabine (DRUG).
Who is sponsoring clinical trial NCT01147939?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01147939 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01147939's enrollment target sits among peer trials
381 3rd of 29 higher than 27 of 29 other Acute Myeloid Leukemia (AML) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia (AML) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RECRUITING · Phase 3
-
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
COMPLETED · Phase 3
-
Ivosidenib as Post-HSCT Maintenance for AML
RECRUITING · Phase 2
-
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia